

## PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



### Kv7.4 Peptide

Cat No.: BS5773P

#### Background

Epilepsy affects about 0.5% of the world's population and has a large genetic component. Epilepsy results from an electrical hyperexcitability in the central nervous system. Potassium channels are important regulators of electrical signaling, determining the firing properties and responsiveness of a variety of neurons. Benign familial neonatal convulsions (BFNC), an autosomal dominant epilepsy of infancy, has been shown to be caused by mutations in the KCNQ2 or the KCNQ3 potassium channel genes. KCNQ2 and KCNQ3 are voltage-gated potassium channel proteins with six putative transmembrane domains. Both proteins display a broad distribution within the brain, with expression patterns that largely overlap. Mutations of KCNQ4 affect the functions of sensory outer hair cells and lead to deafness.

#### Swiss-Prot

P56696

#### Applications

#### Blocking

#### Specificity

This peptide can be used with studies using BS5773 Kv7.4 pAb.

#### Purification & Purity

Synthetic peptide Kv7.4. (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### Product

1 mg/ml in DI water.

#### Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

#### Research Use

For research use only, not for use in diagnostic procedure.

Bioworld Technology, Inc.

1660 South Highway 100, Suite 500 St. Louis Park, MN

55416, USA.

Email: [info@bioworlde.com](mailto:info@bioworlde.com)

Tel: 6123263284

Fax: 6122933841

Bioworld technology, co, Ltd.

No 9, weidi road Qixia District Nanjing, 210046,

P, R.China.

Email: [info@biogot.com](mailto:info@biogot.com)

Tel: +86-025-68037686

Fax: +86-025-68035151